oxymetazoline (oxymetazoline)
Code: R01A A05
Agents acting on the respiratory system (R)
Composition of the medicinal product:
active ingredient: oxymetazoline;
1 ml of solution contains oxymetazoline hydrochloride 0.5 mg;
excipients: benzalkonium chloride, racemic camphor, racemic menthol, eucalyptol, disodium edetate, propylene glycol, sodium dihydrogen phosphate dihydrate, sodium hydroxide or concentrated hydrochloric acid, purified water.
Dosage form.
Nasal spray.
Colorless or slightly yellowish, clear liquid with a specific odor. Opalescence is allowed.
Name and location of the manufacturer.
LLC "Research Plant" DNTSLZ ".
Ukraine, 61057 Kharkiv, Vorobyova St., 8.
Pharmacotherapeutic group.
Anti-edematous and other drugs for local use in diseases of the nasal cavity. Sympathomimetics. ATC code R01A A05.
Vasoconstrictor, decongestant. Stimulates? 2-adrenoreceptors of the sympathetic nervous system. When used intranasally, it causes narrowing of the arterioles of the nasal mucosa, reducing its edema and hyperemia, reduces exudation, restores nasal breathing, reduces the severity of rhinorrhea. Reduces edema of the mucous membrane of the Eustachian tubes, improving drainage in eustachitis and otitis media.
The effect of the drug is manifested 15 minutes after application. Duration of action - 10 - 12 hours.
When applied topically, oxymetazoline is almost not subject to systemic absorption, so its concentration in the blood plasma is insignificant. It is excreted mainly unchanged by the kidneys and intestines.
Indications for use.
Acute respiratory diseases accompanied by nasal congestion. Allergic rhinitis. Vasomotor rhinitis. To restore drainage and nasal breathing in diseases of the paranasal sinuses of the nasal cavity, eustachitis, otitis media. To eliminate edema before diagnostic manipulations in the nasal passages.
Contraindication.
Hypersensitivity to the components of the drug. Atrophic rhinitis; use of monoamine oxidase inhibitors and other drugs that contribute to an increase in blood pressure; increased intraocular pressure, especially in angle-closure glaucoma; severe forms of cardiovascular diseases (arterial hypertension, angina); pheochromocytoma; metabolic disorders (hyperthyroidism, diabetes). Pregnancy and breastfeeding. Children under 6 years of age.
Proper safety precautions during use.
Prolonged use and overdose of the drug should be avoided. Prolonged use of the decongestant may lead to a weakening of its effect. Abuse of this drug may cause atrophy of the mucous membrane and reactive hyperemia with rhinitis medicamentosa, as well as damage to the mucous epithelium and inhibition of epithelial activity. Doses above the recommended ones should be used only under the supervision of a physician.
Special precautions.
Use during pregnancy or breastfeeding.
The drug is contraindicated during pregnancy. If necessary, breastfeeding should be discontinued.
The ability to influence the reaction speed when driving or working with other mechanisms.
After prolonged use of the drug in doses exceeding the recommended ones, a general effect on the cardiovascular system cannot be excluded. In such cases, the ability to drive may be impaired.
Children.
Do not use the drug in children under 6 years of age.
Method of administration and doses.
Adults and children over 12 years of age are prescribed 1 injection into each nostril 2-3 times a day; children aged 6 to 12 years - 1 injection into each nostril 2 times a day. The course of treatment is no more than 5-7 days.
The bottle nozzle is inserted into each nasal passage and the bottle is sharply pressed once during inhalation.
Overdose.
Symptoms: constriction of the pupils, nausea, vomiting, cyanosis, fever, tachycardia, arrhythmia, collapse, vascular insufficiency, arterial hypertension, respiratory disorders, pulmonary edema, cardiac arrest.
In addition, mental disorders may occur, as well as depression of the central nervous system functions, accompanied by drowsiness, decreased body temperature, bradycardia, arterial hypotension, respiratory arrest, and possible development of coma.
Treatment: gastric lavage, administration of activated charcoal, ventilation of the lungs. Phentolamine should be used if blood pressure is low. Vasopressors should not be taken. If necessary, anticonvulsant therapy is indicated.
Interaction with other drugs and other types of interactions.
With the simultaneous use of MAO blockers and tricyclic antidepressants, an increase in blood pressure is possible.
Previous use of timolol in the form of eye drops may reduce the vasoconstrictor effect of the drug.
Concomitant use of other vasoconstrictor drugs increases the risk of side effects.
Expiration date.
2 years.
Storage conditions.
Store in a place protected from light at a temperature of 15 °C to 25 °C.
Keep out of reach of children.
Packaging.
For 15 ml in a container.
Vacation category.
Without a prescription.
